Background. Embolism from unstable atheromas in the carotid bifurcation is a major cause of stroke. Here, we analysed gene expression in endarterectomies from patients with symptomatic (S) and asymptomatic (AS) carotid stenosis to identify pathways linked to plaque instability.
Methods. Microarrays were prepared from plaques (n = 127) and peripheral blood samples (n = 96) of S and AS patients. Gene set enrichment, pathway mapping and network analyses of differentially expressed genes were performed.
Results. These studies revealed upregulation of haemoglobin metabolism (P = 2.20E-05) and bone resorption (P = 9.63E-04) in S patients. Analysis of subgroups of patients indicated enrichment of calcification and osteoblast differentiation in S patients on statins, as well as inflammation and apoptosis in plaques removed >1 month compared to <2 weeks after symptom. By prediction profiling, a panel of 30 genes, mostly transcription factors, discriminated between plaques from S versus AS patients with 78% accuracy. By meta-analysis, common gene networks associated with atherosclerosis mapped to hypoxia, chemokines, calcification, actin cytoskeleton and extracellular matrix. A set of dysregulated genes (LMOD1, SYNPO2, PLIN2 and PPBP) previously not described in atherosclerosis were identified from microarrays and validated by quantitative PCR and immunohistochemistry.
Conclusions. Our findings confirmed a central role for inflammation and proteases in plaque instability, and highlighted haemoglobin metabolism and bone resorption as important pathways. Subgroup analysis suggested prolonged inflammation following the symptoms of plaque instability and calcification as a possible stabilizing mechanism by statins. In addition, transcripIntroduction Atherosclerotic plaque rupture followed by myocardial infarction or stroke is the major cause of morbidity and mortality in patients with cardiovascular disease. In order to improve identification of individuals at risk and to facilitate the development of future preventive therapeutic strategies, there is a need for better understanding of the pathophysiology underlying the transition of atherosclerosis from clinically asymptomatic (AS) *These authors contributed equally. and stable lesions to symptomatic (S) and unstable disease [1] .
The unstable atheroma has previously been characterized by enhanced activity of proinflammatory T cells and macrophages, increased cytokine release and secretion of matrix metalloproteinases (MMPs), thinning of the fibrous cap due to impaired collagen fibre formation, collagenolysis and cell apoptosis. Together with haemodynamic forces, these processes lead to fibrous cap rupture, exposure of tissue factor, atherothrombosis and clinical manifestations [1, 2] .
Embolization of ruptured plaques in the carotid bifurcation to the cerebral circulation can occur, causing transient or permanent ischaemia. Patients with high-grade carotid stenosis are treated with stroke preventive interventions, but neither laboratory tests nor imaging have been clinically established for precise detection of unstable individuals or lesions [3] . A number of clinical parameters influence the risk of stroke in patients with carotid stenosis. AS carotid disease is associated with an annual stroke risk of 1-3%, whereas S patients with either transient ischaemic attack (TIA) or minor stroke (MS) have a more than 10-fold increased risk [4] . In addition, it has been shown that TIA and MS confer a higher risk than ocular symptoms [retinal TIA, amaurosis fugax; (AF)] [3] . Recurrent embolization and symptoms are most pronounced within the first 2 weeks after the index event [5, 6] and are thereafter gradually reduced. Medical therapy with HMG CoA reductase inhibitors (statins) significantly reduces stroke risk, probably by improving plaque stability [7, 8] .
Large-scale transcriptomic analyses using microarrays enable studies of expression patterns to be performed for thousands of genes simultaneously [9] . Although alternative technologies such as RNA sequencing are becoming available, microarrays remain powerful tools for investigations of disease-related gene expression changes, particularly when combined with open-source software for high-throughput data exchange (e.g. Gene Expression Omnibus (GEO) data sets and ArrayExpress) and a growing number of web-based programs for functional analysis. Previous attempts to investigate global gene expression profiles in human atherosclerotic plaques [10] [11] [12] [13] [14] [15] have been restricted by small sample sizes, the lack of undiseased (nonatherosclerotic) vascular control tissues or the inability to classify patients based on clinical categories. Hence, factors determining plaque vulnerability and healing remain largely unknown.
The Biobank of Karolinska Endarterectomy (BiKE) was established in 2002 for prospective collection of atherosclerotic plaque tissue and blood from patients undergoing carotid endarterectomy for high-grade carotid artery stenosis, with a database of clinical parameters including risk factors, medication, symptoms, time of surgery, preoperative imaging and anthropometric and laboratory measurements. Transcriptomic and genomic profiles have been generated by microarray and genotyping chips, enabling multivariate analysis of gene expression patterns in relation to clinical parameters and genotype. Data from this biobank have been utilized previously, both in hypothesis-driven and hypothesis-independent studies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In this study, we postulated that phenotypes of patients with carotid atherosclerosis would correlate with specific gene expression patterns and we analysed the global transcriptome in relationship to clinical features stratifying stroke risk. We have been able to identify novel molecular signatures and pathways of plaque instability, validate established processes featuring late-stage atherosclerosis as well as to highlight the temporal dynamics and modulation of atherosclerosis by statin therapy.
Materials and methods

Human material
Patients undergoing surgery for S or AS, highgrade (>50% North American Symptomatic Carotid Endarterectomy Trial, NASCET) [32] carotid stenosis at the Department of Vascular Surgery, Karolinska University Hospital, were consecutively enrolled in the study. Informed consent was obtained, and clinical data were recorded on admission. The following clinical parameters were selected for investigation in this study: presence and type of symptoms; statin treatment; and time between last symptom and surgery. Symptoms of plaque instability were defined as TIA, MS and AF. TIA was defined as a transient episode of neurological dysfunction, and MS as symptoms persisting >24 h with complete or nearly complete recovery.
results from the Asymptomatic Carotid Surgery Trial (ACST) [33] . Patients with atrial fibrillation and those who had suffered a major stroke were excluded from the study. Carotid endarterectomies (carotid plaques, CP) and peripheral blood samples were collected at surgery and retained within the BiKE. Plaques were divided transversally by the surgeon at the most stenotic part, and the proximal half of the lesion used for RNA preparation and the distal half fixed in 4% Zn-formaldehyde and processed for histology. RNA from tissues and peripheral blood mononuclear cells (PBMCs) was analysed by gene expression microarrays, and gene expression in plaques was validated by quantitative PCR (qPCR). A summary of the samples used in the study is provided in Fig. 1a , and demographics of the cohort are given in Table S1 . Nonatherosclerotic, further referred to as normal artery (NA), control samples were obtained from nine macroscopically disease-free iliac arteries and one aorta from organ donors without a history of cardiovascular disease. The vessels were dissected and the intima and media used for RNA isolation and arrays. NAs for immunohistochemistry (IHC) were radial arteries obtained at coronary bypass surgery and one control internal carotid artery from a 61-year-old man undergoing surgical excision of a neck tumour. All samples were collected with informed consent from patients and organ donors or their guardians. The study was approved by the regional ethics committee.
Antibodies
A summary of the primary antibodies kindly provided by the Human Protein Atlas (HPA) project is shown in Table S2 with information about the corresponding gene function and tissue expression pattern obtained from www.proteinatlas.org. For colocalization, the following antibodies for cell type-specific markers were used as recommended by the manufacturers: anti-alpha smooth muscle actin (aSMA; #M0851; DAKO, Glostrup, Denmark), CD61 (#M0753; DAKO) and CD68 (#NCL-L-CD68; Novocastra, Newcastle, UK).
RNA extraction
Plaques were frozen at À80°C immediately after surgery, and peripheral blood was processed according to standard procedures for separation of the mononuclear cell fraction and RNA isolation. Briefly, whole blood was collected at surgery and subjected to density gradient centrifugation through Ficoll-Paque preparation tubes (Vacutainer CPT, Becton-Dickinson, Franklin Lakes, NJ, USA). PBMCs were resuspended using RLT buffer (Qiagen, Hilden, Germany) before freezing at À80°C. RNA was prepared using Qiazol Lysis Principal components analysis of discovery data set from plaque tissues for symptomatic and asymptomatic patients based on expression values shows random scattering of the samples in groups and no clustering. The first two principal components (PC1 and PC2) explain 23% and 22%, respectively, of variance amongst samples in this comparison. PBMC, peripheral blood mononuclear cell; S, symptomatic; AS, asymptomatic; qPCR, quantitative PCR; TIA, transient ischaemic attack; MS, minor stroke; AF, amaurosis fugax.
Reagent (Qiagen) and purified using the RNeasy Mini kit (74106, Qiagen), including DNase digestion. The concentration of RNA was measured using Nanodrop ND-1000 (Thermo Scientific, Waltham, MA, USA) and quality estimated using a Bioanalyser capillary electrophoresis system (Agilent Technologies, Santa Clara, CA, USA). For microarrays, only RNA of good integrity (RNA Integrity Number >7), A260/A280 ratio 1.8-2.1, A260/230 ratio 0.7-1.5 and concentration about 50-500 ng lL À1 was used, according to recommended standards for whole-transcript arrays.
Microarray analysis
Gene expression analyses of 127 endarterectomy samples were performed in two batches using Affymetrix HG-U133 plus 2.0 Genechip arrays (Santa Clara, CA, USA). A separate analysis was performed on an additional 50 samples using Affymetrix HG-U133a Genechip arrays. Robust multi-array average normalization, filtering of probesets based on signal intensity and batch effect correction were performed, and processed gene expression data were recorded on a log 2 scale as previously described [16, 23] . The full data set is available from Gene Expression Omnibus (accession number GSE21545).
Data analyses
Data set analyses were performed with GraphPad Prism 6 and Bioconductor using a linear regression model adjusted for age and gender and a two-sided Student's t-test assuming nonequal deviation, with correction for multiple comparisons performed according to the method of Sidak-Bonferroni [34] . Spearman correlations with Benjamini-Hoechberg correction were calculated to determine the association between mRNA expression levels from microarrays. In all analyses, P-values <0.05 were considered statistically significant, although raw Pvalues are also reported. The following publically available programs were used for functional analyses of the microarray data sets: ArrayMining [35] , GOrilla and DAVID for gene set enrichment analyses (GSEAs) based on functional grouping of genes defined in gene ontology (GO) categories [raw P-values reported with false discovery rate (FDR) correction; categories with more than one gene and nonoverlapping gene sets considered]; INMEX for meta-analysis using Fisher's weight-free method for combined P-values [36] ; GeneMania for functional network construction; PINA [37, 38] and Cytoscape for protein-protein interactome network analyses; MSigDB (Broad Institute) for mapping of transcription factors and microRNA motif binding sites (FDR set to 1%). Information about individual genes and proteins was extracted from www.-genecards.org, www.noncode.org and www.uniprot.org. Prediction modelling was performed based on sparse partial least square-discriminant analysis (sPLS-DA) [39] . Statistical resampling was used to balance the number of S and AS patients in the analysis. In order to optimize the prediction performance, a nested cross-validation machine learning method was applied: the samples were randomly divided into one training set and one test set as an independent hold-out set for validation. Within the training set, the samples were randomly divided into subtraining sets and subtest sets. The sPLS-DA model was built on the training set. The prediction error rate was estimated by classifying a subset of test samples. The prediction accuracy was determined by performing a 10-fold crossvalidation. New sPLS-DA models were built sequentially by including different numbers of variables in the model, and prediction error rates were determined. Then, the final sPLS-DA model was constructed with the minimum number of variables selected for achieving the smallest prediction error rate. One dimension of sPLS-DA was used in the model. The independent hold-out test set was predicted based on this final model.
qPCR
For qPCR, total RNA was reverse-transcribed using the High-capacity RNA-to-cDNA Kit (4387406; Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA). PCR amplification was performed in 96-well plates using the 7900 HT real-time PCR system (Applied Biosystems), TaqMan Universal PCR Master Mix (Applied Biosystems) and TaqMan Gene Expression Assays (LMOD1 Hs00201704_m1, SYNPO2 Hs003264 93_m1, PPBP Hs00234077_m1, PLIN2 Hs00605 340_m1; Applied Biosystems). All samples were measured in duplicate. Results were normalized relative to the equal mass of total RNA as well as the Ct values of the RPLPO housekeeping control gene (probe Hs99999902_m1). The relative amount of target gene mRNA was calculated by the 2 (ÀDDC t ) method and presented as fold change compared to the average baseline expression in normal arteries. The qPCR results were evaluated using the nonparametric Mann-Whitney U-test.
IHC
All IHC reagents were purchased from Biocare Medical (Concord, CA, USA). Isotype rabbit and mouse IgG were used as negative controls. In brief, 5-lm sections were deparaffinized in Tissue Clear and rehydrated in a graded series of ethanol concentrations. For antigen retrieval, slides were subjected to high-pressure boiling in DIVA buffer (pH 6.0). After blocking with Background Sniper, primary antibodies diluted in Da Vinci Green solution were applied and incubated at room temperature for 1 h. A double-stain probe-polymer system containing alkaline phosphatase and horseradish peroxidase was applied, with subsequent detection using Warp Red and Vina Green. Slides were counterstained with Haematoxylin QS (Vector Laboratories, Burlingame, CA, USA), dehydrated and mounted in Pertex (Histolab, Gothenburg, Sweden). Images were captured using a Nikon OPTIPHOT-2 microscope equipped with a digital camera and processed with NIS-Elements software.
Results
Characterization of gene expression differences in patient subgroups
Plaques from 127 consecutively enrolled patients (40 AS and 87 S) were analysed by gene expression microarrays (discovery data set). An overlapping subset of 96 PBMC preparations (30 AS and 66 S patients) was separately analysed by microarray profiling. A nonoverlapping set of 50 plaques (10 AS and 40 S patients) was analysed with a different microarray platform and used as an independent validation cohort. In addition, RNA from 77 nonoverlapping plaques (21 AS and 56 S patients) was used for qPCR validation of the microarray results. A summary of these cohorts and the study workflow is shown in Fig. 1a .
Pairwise comparisons of microarray profiles from the discovery data set were assessed as outlined in Fig. 1b , by grouping the patients into clinically defined categories. The majority of the study cohort was male (78%); S patients were generally older than AS patients (mean age 72.5 vs. 66.4, P = 0.0002) and had significantly lower mean haemoglobin (Hb) levels (131.55 vs. 141.62 g L À1 , P = 0.0077). The demographic characteristics are shown in detail in Table S1 . Principal components analysis, performed to give an overview of the expression data distribution in S and AS tissue samples (Fig. 1c) , showed that these patient groups roughly cluster together with 23.6% and 22.2% variability explained by the first two principal components. These results emphasize subtle biological differences that reflect the overall gene expression patterns in plaques from S and AS patients.
Hb metabolism and bone resorption are enriched in plaques from S patients
Analyses of plaques isolated from S and AS patients revealed small differences in gene expression levels (up to 2-fold change). The fraction of differentially regulated probesets was <5%. In this analysis, many genes were identified that have previously not been reported in similar comparisons, for example ADM, PPBP, MARCO and MREG (Table 1; for full list see Table S3 ), in addition to those already established in atherosclerosis, such as matrix metalloproteinases (MMPs), markers of macrophages, chemokines, cathepsins and apolipoproteins that were upregulated and markers of differentiated smooth muscle cells (SMCs) that were downregulated [10, 14, 23, 40] . GSEA on GO categories for the differentially expressed genes in plaques from S patients showed enrichment of low-density lipoprotein particle clearance, inflammatory response, macrophage-derived foam cell differentiation, cell proliferation, apoptosis, angiogenesis and extracellular matrix (ECM) disassembly. It is interesting that enrichment was also observed for positive regulation of bone resorption (Tables 2 and S5 ). There were also small differences in gene expression (up to 1.5-fold change; overall about 1% differentially regulated probesets; Tables 1 and S4) in PBMCs from S versus AS patients. Here, we observed upregulation of a number of genes including HBB, CA1, IFNG, F8, ALAS2, ARG2, ARSD and SELENBP1. Apart from HBB, several genes implicated in erythropoiesis were also upregulated, particularly GATA2, ERAF and KLF1. Even genes associated with Hb catabolism were upregulated, including iron-binding PIR, OGFOD1 and several members of the cytochrome P450 family such as CYP2B6 and CYP26A1. The most enriched pathways were response to nitrosative stress, positive regulation of nitric oxide biosynthesis, IL1B secretion, lymphocyte activation and Hb metabolism (Tables 2 and S5 ).
We also assessed gene expression differences in subgroups of clinical phenotypes of S patients, which consequently reduced sample size and statistical power. Gene expression profiles in patients with TIA and MS were compared to those in patients with AF because it has been shown that patients with TIA and MS have an increased stroke risk [41] . Small differences in expression levels (up to 1.5-fold change) and in the number of differentially regulated probesets (about 3%; Table S6) were observed. Here, several genes associated with platelet activation, such as TUBB1, PTAFR, TREML1 and platelet-specific GP6, were strongly upregulated in patients with TIA and MS. GSEA highlighted angiogenesis, oxidoreductase activity, secretion, chemotaxis and inflammation as processes enriched in plaques of S patients with TIA and MS (Table S9) . Categorization of patients with respect to time from last qualifying symptom to surgery surprisingly yielded marked differences in gene expression. A higher relative fold change (up to 10-fold) and more differentially expressed probesets (about 20%) were found in this than in other comparisons (Table S7) . Of note, prolonged immune system activation and apoptosis were ongoing in plaques extracted 1 month or later after symptom as compared to those removed within the first 2 weeks (Table S9) . We also investigated differences between S patients treated with statins compared to those who did not receive this therapy. As expected, serum cholesterol and LDL cholesterol levels were significantly decreased in the treated group (mean difference AE SD À0.7204 AE 0.3310 mmol L
À1
, P = 0.03 and À0.8782 AE 0.3321 mmol L
, P = 0.01, respectively). Comparison of gene expression in lesions from S patients with and without statin treatment showed modest differences in fold change (up to 2.5-fold), but an abundance of differentially expressed probesets (about 15%; Table S8 ). Notably, regulation of calcium-mediated signalling, osteoblast differentiation and negative regulation of angiogenesis and inflammatory response were enriched in S patients receiving statin treatment (Table S9 ).
For comparison, gene expression alterations in atherosclerotic CP tissue compared with NA tissue were considerable (up to 274-fold change for MMP12) with a larger portion of dysregulated probesets (25%), reflecting the profound biological differences in these tissues. In plaques, pathways of cell proliferation, nitric oxide signalling, lipoprotein and apoptotic particle clearance, activation of immune cells, chemokine secretion, blood coagulation and ECM disassembly were all enriched ( Fig. S1a-c) and, as in PBMCs, the Hb-haptoglobin (Hp) complex was one of the most dominant GO categories. In confirmation, generally similar results were obtained when pathways were analysed in a separate microarray data set of n = 50 plaques (Fig. S1d) .
MALAT1, MIR155HG and TP53TG are involved in the regulation of gene expression in carotid atherosclerosis
Gene expression analyses in plaques and PBMCs from patients with carotid atherosclerosis also revealed dysregulation of many noncoding (nc) transcripts (selected ncRNAs are presented in Fig. 2a ; for full list see Table S10 ). MIR155HG, found in activated B and T cells and macrophages, was significantly upregulated in comparisons between S and AS plaques and PBMCs. The long noncoding (lnc) RNA MALAT1 associated with cell proliferation, apoptosis [42] , neovascularization [43] and prostate cancer [44] was substantially LDL particle clearance was the most enriched category in comparisons between plaques from symptomatic (S) and asymptomatic (AS) patients. In peripheral blood mononuclear cells (PBMCs), nitric oxide biosynthesis, haemoglobin metabolism, lymphocyte activation and IL1B secretion were dominant in cells from S versus AS patients. Adjusted Pvalues are shown; expanded pathway analyses are shown in the Table S5 . Enrichment was calculated as (b/n)/(B/N), where N is the total number of genes, B is the total number of genes associated with a specific GO term, n is the number of genes in the target set and b is the number of genes in the intersection.
downregulated in S compared with AS plaque tissue, and in comparison TIA+MS versus AF patients. By contrast, MALAT1 was upregulated in plaques extracted >1 month after the symptoms compared to those removed within 2 weeks. TP53TG lncRNA regulating p53 expression [45] was repressed in TIA+MS compared with AF patients.
To investigate the regulation through transcription factors and miRNAs, we performed reverse analysis by mapping for the corresponding binding motifs in genes differentially expressed between S and AS patients. This approach confirmed enrichment of factors involved in regulation of the immune response, response to cytokines, expression by liver, angiogenesis and muscle expansion ( Fig. 2b ; for full list see Table S11 ).
A panel of 30 genes discriminates between plaques from S and AS patients
Prediction modelling was performed to determine molecular signatures for classification of plaques from S versus AS patients. A panel of 30 genes was found to be capable of predicting S and AS lesions with 78% accuracy, and 47% and 7% variability explained by the first two principal components respectively (Fig. 3) . Of interest, many of these genes, such as HCG11, DNAJC19, ZNF41, ZNF493 and RPL9, were involved in transcriptional regulation (Table S12 ). The panel also included genes associated with lysosomes (PIK3C3 and CNO), cytokine signalling (ASB1), cholesterol distribution (TSPO2) and the ECM (CRTAC1).
Functional gene networks in carotid atherosclerosis
A meta-analysis was performed using a similar published data set [14] of CP samples from a smaller cohort of S and AS patients (12 S and 9 AS) with the same microarray platform and technical requirements as the BiKE. This analysis showed about 20% overlap in significantly differentially expressed probesets ( Fig. 4a ; for full list see Table S13 ), such as CCL18, MMP12, CTSZ, CD36, CD163, IGFBP4, FABP5, GLUL, MYH11, SMTN, MYOCD and CNN1. From the full list of metagenes, 85 of the most commonly reported and well characterized in atherosclerosis [23, 40] were selected for functional network construction (Fig. 4c) , and GSEA showed that they were mainly involved in ECM organization (FDR 1.53E-09), inflammation (FDR 3.71E-03), angiogenesis (FDR 3.46E-03) and response to hypoxia (FDR 1.52E-02). Overall, 87% of these genes exhibited strong positive expression cross-correlations in the BiKE, many with Spearman r > 0.90 and P < 10E-30 (e.g. MMP12 and MMP9 with CD36 and CD163 markers of macrophages; see representative heat plot in Fig. 4b and for full data see Table S14 ). When meta-genes were connected into an extended protein-protein interaction network, key interaction nodes were centred around Hif1a, Actn2, Cxcr4, S100A9, S100A10, Casp4, Hspg1, Ubc, Pdlim7, Nos1, Hspa6 and Egfr (Fig. 4d) .
LMOD1, SYNPO2, PPBP and PLIN2 are dysregulated in carotid atherosclerosis
Many genes were identified in this study that had previously not or only poorly been characterized in atherosclerosis. Several strongly dysregulated genes, representative of different cell types based on publically available information (Table S2) , were chosen for validation by IHC and qPCR. LMOD1 and SYNPO2 were downregulated in CP versus NA microarrays (mean difference AE SD À2.405 AE 0.2162, P < 0.0001 and À4.256 AE 0.2827, P < 0.0001, respectively) and in microarrays comparing S and AS patients (mean difference À1.431 AE 0.5172, P < 0.0001 and À1.709 AE 0.3711, (a) (b) Fig. 3 Prediction modelling for genes discriminating between plaques from symptomatic (S) and asymptomatic (AS) patients. Heat plot showing expression profile for a panel of 30 genes (a; patients presented on the x-axis) found to discriminate between plaques from S and AS patients with high accuracy as shown by the principal components analysis (b).
P < 0.0001, respectively). PPBP and PLIN2 were upregulated in CP versus NA tissues (mean difference 3.560 AE 0.3138, P < 0.0001 and 2.640 AE 0.2852, P < 0.0001, respectively) as well as in S versus AS patients (mean difference 1.439 AE 0.5253, P < 0.0001 and 1.564 AE 0.6460, P < 0.0001, respectively; Fig. 5a ). The same trends for these genes were replicated in the microarray validation data set (n = 50 patients; data not shown) and qPCR analysis in a separate subcohort of patients (n = 77, Fig. 5b ): LMOD1 and SYNPO2 were significantly downregulated in CP compared with NA tissues (mean difference À0.5654 AE 0.2078 and À0.9424 AE 0.1668, respectively) and PPBP and PLIN2 were upregulated (mean difference 32.25 AE 12.40 and 8.701 AE 1.156, respectively). The corresponding proteins were localized in plaques and normal internal carotid artery by IHC ( Fig. 5c ; for additional images and higher magnifications see Fig. S2 ). Ppbp (CXCL7) co-localized with the platelet marker CD61 in areas of intraplaque haemorrhage (IPH). Plin2 (perilipin 2) was co-localized with the macrophage receptor CD68 mainly in foam cells. Lmod1 (leiomodin 1) and Synpo2 (synaptopodin 2) were expressed strictly by aSMA-positive SMCs in the NA media, and no staining for these two proteins was observed in CPs. Expression correlations for LMOD1 and SYNPO2 in plaque arrays were positive solely with markers of differentiated SMCs whereas negative correlations were observed with cytokines, ECM degrading enzymes and inflammation markers (Table S15) .
Discussion
Here, we present a comprehensive transcriptomic analysis of human end-stage carotid atherosclerosis in relationship to clinical parameters of plaque instability. We confirm established features of vulnerable plaques and patients, but also reveal novel pathways and gene signatures determining disease phenotype. Data suggesting enhanced calcification in patients on statin therapy and rapid tissue repair followed by prolonged inflammation after plaque rupture were new observations that may be related to plaque stabilization, whilst, that is, processes associated with intraplaque haemorrhage persisted in connection with vulnerable lesions. Coordination of gene expression and transcription-regulating elements was shown to be essential in controlling the subtle overall differences between S and AS disease. Importantly, many genes and candidate transcriptomic biomarkers previously not characterized in unstable atheroma were identified in our study.
Modest alterations in gene expression levels were found in plaques and PBMCs from S and AS patients, probably because these two groups represent entities of the same underlying disease [14, 46] . Despite a reduction in sample size and statistical power, we also compared gene expression between different subgroups of patient phenotypes. It is interesting that more significant gene expression differences were observed when comparisons were based on either the time between index symptoms and surgery or whether or not patients received statin therapy. In S patients treated with statins, pathways previously associated with plaque stability such as suppression of angiogenesis and MMPs were enriched. Notably, dysregulation of genes associated with the HMG CoA reductase pathway, such as AMFR [47] , indicated direct effects of statins on plaques. With respect to the pleiotropic influence of statins, the documented decrease in cholesterol and LDL levels also indicates effects related to lipid lowering in these patients [48] . Enrichment of pathways associated with plaque calcification, such as regulation of calcium-mediated signalling and osteoblast differentiation, is a novel finding with this methodological approach. This finding suggests that statins promote plaque stability as calcified plaques have been associated with AS carotid disease [49] and statins have also been shown to increase vascular calcification [50, 51] . Interestingly, in the entire group of plaques from S patients, bone resorption emerged as one of the enriched pathways. Taken together, these results suggest that statins mediate plaque stabilization through calcification and by counteracting resorption of calcified tissue. Mechanistically, these effects may be related to the lipid-lowering effects of the treatment as hyperlipidaemia has been shown to enhance osteoclast activity [52] .
Because the risk of stroke in S patients with carotid stenosis decreases over time [4] , plaques removed at different intervals after symptoms may represent time-dependent changes in plaque phenotype.
Comparison of gene expression in plaques from S patients who underwent surgery >1 month versus <2 weeks after symptom indicated altered plaque biology following plaque rupture [23, 24, 53] , with recurrent upregulation of inflammatory processes in the later phases of the healing response and downregulation of pathways associated with tissue regeneration. One of the most repressed genes was MSTN, encoding a protein that regulates muscle growth [54] . These findings are in contrast to those of some earlier studies [24, 53] , but support previous conclusions from this cohort, and suggest that the initial period after plaque rupture involves a rapid initiation of tissue repair and SMC proliferation followed by a prolonged immune response in the resolution phase towards restored plaque stability [23] .
Intraplaque haemorrhage, involving release from red blood cells of Hb that is subsequently bound by Hp to prevent oxidation [55] , has previously been recognized in association with plaque instability. In line with this, we found significantly lower Hb levels in S patients in our cohort. Furthermore, the Hb-Hp complex was one of the most enriched GO categories in plaques and Hb metabolism was enriched in PBMCs. A common genetic variant of Hp has recently been associated with cardiovascular disease risk in multiple independent cohorts, both in plaques and in peripheral blood [56] [57] [58] , and Hp genotyping has been recommended for risk identification and treatment optimization [56] .
IL-1B secretion appeared as a major pathway in PBMCs and in CP tissue. In support of this observation, activation of IL-1B by cholesterol has been reported in coronary atherosclerosis, and neutralization of IL-1B by a human monoclonal antibody canakinumab has been shown to reduce inflammation; this antibody is being investigated as an attractive therapy for atherosclerosis [59] .
In patients with increased stroke risk (TIA/MS), compared with those with AF [60] , processes previously associated with unstable lesions such as angiogenesis [61] were enriched and the most upregulated gene was TUBB1, a platelet-specific tubulin variant linked to cardiovascular disease risk [62] . PTAFR (platelet-activating factor receptor), GP6 (platelet-specific glycoprotein VI) and genes from the TREML family involved in platelet aggregation, inflammation and activation were also upregulated. These findings support the notion that plaque rupture with platelet activation is more prevalent in patients with TIA/MS than in those with ocular symptoms [63] .
Here, we have shown that the profile of transcription factors in S compared with AS plaques reflects the same main pathways as in the gene expression analysis, and prediction modelling further emphasized a central role for transcriptional regulation in determination of patient phenotype. Previously, we have reported that the predictive value of plaques for risk profiling is superior to that of blood samples [16] . The common gene expression patterns in S and AS plaques, especially those related to chemokine signalling, apoptosis and calcification, were highlighted in meta-analyses using another publicly available data set. Together, these results suggest that the fine determination of atherosclerosis state requires coordinated regulation by multiple factors and plaque-specific networks. It is conceivable that end-stage atherosclerosis consists of an array of processes where minor alterations in plaque biology shift the balance from a stable AS lesion to atherothrombosis and clinical symptoms. Similar observations have recently been reported in cancers [44] .
Many studies of novel target genes in atherosclerosis using data from the BiKE have already been reported [21, 23, 24, 29] . Here, the analysis revealed additional genes that had not previously been associated with atherosclerosis, of which several were selected for replication in a nonoverlapping set of patients. LMOD1 (Leiomodin 1) has been predicted to be an SMC-specific gene [64] and an SRF/ MYOCD-dependent transcript [65] and SYNPO2 (Synaptopodin 2) was predicted to be associated with SMC cytoskeletal organization [66] . Because LMOD1 and SYNPO2 were strongly downregulated in plaques and correlated with all markers of differentiated SMCs, they may represent novel markers of SMC phenotype and should be explored in the context of SMC function in atherosclerosis. The megakaryocyte PPBP gene product CXCL7 is a platelet chemokine involved in vessel repair after vascular injury [67] and was found in the present study in plaques with IPH. Plin2 was detected in foam cells and cholesterol clefts within the necrotic core of plaques. Perilipin has previously been described as an adipocyte protein that coats intracellular lipid droplets. It was proposed to contribute to inhibition of lipolysis [68, 69] and thus could promote plaque vulnerability through increased lipid accumulation. Because of their association with IPH and lipid content, PPBP and Plin2 may be interesting new candidate transcriptomic biomarkers of unstable atheroma.
A limitation of this study is that the BiKE cohort comprises only advanced lesions (American Heart Association grades IV and V), and therefore cannot provide information about disease progression. This restricts the generalization of the present results to high-risk populations with end-stage disease. It is most likely that the phenotyping of patients based on the presence or absence of cerebral symptoms was insufficient to completely exclude overlap between the groups, as lesions from AS patients may vary with regard to morphological features of plaque instability [46] . Unfortunately, histological plaque classification [70] was incompatible with the sampling protocol used here. In analyses of time-dependent gene expression changes in plaques, two separate time-points were defined, as too few patients underwent surgery in the period between 2 weeks and 1 month after symptoms. In addition, comparisons based on statin medication, time from symptom to surgery and type of symptoms may be underpowered regarding limited group sizes, but nevertheless may provide novel insights into processes related to these clinical categories. Of note, even the smallest subgroups of patients compared in the present study were larger than in most published human atherosclerosis microarray studies.
Consensus is lacking regarding the selection of appropriate control tissues, and arteries of various embryonic origins have been used for this purpose as well as adjacent macroscopically intact parts of lesions [40, 71] . In this study, control vessels contained outer media that is not included in the endarterectomy intimal samples. From a technical viewpoint, it is noteworthy that the gene array platform used here does not provide a complete analysis of ncRNAs. From a conceptual viewpoint, it should be noted that, even if the complexity of large-scale gene expression analyses is reduced by construction of functional networks, this method is limited in its ability to identify novel pathways as it is based on existing literature and databases. We obtained similar overall results in our analyses of independent S versus AS array data sets of different sizes, suggesting that increasing the number of patients does not necessarily improve the discovery of new pathways.
In conclusion, extensive analysis of the transcriptomic landscape in human atherosclerosis, in combination with patient phenotyping, facilitated novel discoveries related to overall plaque instability, time-dependent gene expression changes and medication. Although expression analyses from clinical samples cannot prove a causal relationship between increased gene expression and disease state, our findings provide a powerful platform for further functional and mechanistic exploration of novel molecular signatures in carotid atherosclerosis, which may aid in the development of clinical biomarkers and targeted molecular imaging for identification of vulnerable patients and lesions.
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